 IMPACT FACTOR:
7.274 | | The coupling of pathology with massively parallel sequencing studies provides a unique opportunity to further our understanding of the pathophysiological and pathogenetic mechanisms of human disease, a major interest of The Journal of Pathology. The Journal is now soliciting submissions of primary research based on massively parallel sequencing taking advantage of novel insights into the genetic basis of human diseases, including but not restricted to, the identification of new genotype-phenotype associations and novel driver mutations, characterisation of patterns of genetic instability, and on the topic of intra-tumour genetic heterogeneity. We have recently published a number of such studies: |
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers Natrajan R, Mackay A, Lambros MB, et al., Volume 227, Issue 1, pages 29-41, May 2012 Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer Wu C, Wyatt AW, Lapuk AV, et al., Volume 227, Issue 1, pages 53-61, May 2012 Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities Schrader KA, Heravi-Moussavi A, Waters PJ, et al., Volume 225, Issue 1, pages 12-18, September 2011 Why publish your next generation sequencing study in The Journal of Pathology? - Impact Factor: 7.274
- Your manuscript will be fast-tracked and expertly peer-reviewed
- We aim to give a final decision within 14 days
- We aim for an initial online publication within 7 days of acceptance
- Your article will be made free to view online for 6 months, facilitating dissemination within the community.
Submission Process Submissions should report studies that use massively parallel sequencing technology to address important questions in the pathobiology of disease. Manuscripts should offer new approaches to considering such data, clinically relevant findings and/or functional insights with validation. Timely reviews and perspectives would also be considered. In your covering letter, please mention that the submission is a response to the “massively parallel sequencing studies call”. Please note that the massively parallel sequencing data included in the manuscript must be made publicly available by the time of publication, and full details of the analysis methods should be provided either in the main manuscript or as supplementary methods. |
